


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5767994/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A study of ruxolitinib response–based stratified treatment for pediatric hemophagocytic lymphohistiocytosis. Blood, 2022, 139, 3493-3504.	0.6	30
2	Familial hemophagocytic lymphohistiocytosis onset as central diabetes insipidus in a child. Pediatric Blood and Cancer, 2022, 69, e29684.	0.8	0
3	Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis. Orphanet Journal of Rare Diseases, 2022, 17, 151.	1.2	6
4	Clinical significance of cerebrospinal fluid soluble CD25 in pediatric hemophagocytic lymphohistiocytosis with central nervous system involvement. Pediatric Blood and Cancer, 2022, 69, e29712.	0.8	1
5	18F-FDG PET/CT for Identifying the Potential Primary Diseases and Predicting Prognosis of Secondary Hemophagocytic Lymphohistiocytosis in Children. Contrast Media and Molecular Imaging, 2022, 2022, 1-9.	0.4	3
6	A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis. Haematologica, 2021, 106, 1892-1901.	1.7	36
7	Clinical Analysis of Pediatric Systemic Juvenile Xanthogranulomas: A Retrospective Single-Center Study. Frontiers in Pediatrics, 2021, 9, 672547.	0.9	5
8	Outcome of L-DEP regimen for treatment of pediatric chronic active Epstein–Barr virus infection. Orphanet Journal of Rare Diseases, 2021, 16, 269.	1.2	9
9	Clinical Features and Prognostic Factors of Children with Chronic Active Epstein-Barr Virus Infection: A Retrospective Analysis of a Single Center. Journal of Pediatrics, 2021, 238, 268-274.e2.	0.9	5
10	Second-line regimen for CNS-involved pediatric Langerhans cell histiocytosis. Pituitary, 2021, , 1.	1.6	2
11	Haploidentical haematopoietic stem cell transplantation for malignant infantile osteopetrosis and intermediate osteopetrosis: a retrospective analysis of a single centre. Orphanet Journal of Rare Diseases, 2021, 16, 314.	1.2	7
12	Clinical analysis of chronic active EBV infection with coronary artery dilatation and a matched case–control study. Orphanet Journal of Rare Diseases, 2021, 16, 50.	1.2	4
13	Haploidentical hematopoietic stem cell transplantation for pediatric patients with chronic active Epstein–Barr virus infection: a retrospective analysis of a single center. World Journal of Pediatrics, 2021, 17, 626-636.	0.8	6
14	The Role of Pre-therapeutic 18F-FDG PET/CT in Pediatric Hemophagocytic Lymphohistiocytosis With Epstein-Barr Virus Infection. Frontiers in Medicine, 2021, 8, 836438.	1.2	5
15	Type IV Glycogen Storage Disease Associated With Hemophagocytic Lymphohistiocytosis: A Case Report. Journal of Pediatric Hematology/Oncology, 2020, 42, 368-369.	0.3	5
16	Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children. International Journal of Hematology, 2020, 112, 568-576.	0.7	17
17	Treatment of pediatric primary hemophagocytic lymphohistiocytosis with the HLH-94/2004 regimens and hematopoietic stem cell transplantation in China. Annals of Hematology, 2020, 99, 2255-2263.	0.8	4
18	Osteopontin is highly secreted in the cerebrospinal fluid of patient with posterior pituitary involvement in Langerhans cell histiocytosis. International Journal of Laboratory Hematology, 2020, 42, 788-795.	0.7	3

ANG WEI

#	Article	IF	CITATIONS
19	Associations between PRF1 Ala91Val polymorphism and risk of hemophagocytic lymphohistiocytosis: a meta-analysis based on 1366 subjects. World Journal of Pediatrics, 2020, 16, 598-606.	0.8	6
20	Hemophagocytic lymphohistiocytosis resulting from a cytokine storm triggered by septicemia in a child with chronic granuloma disease: a case report and literature review. BMC Pediatrics, 2020, 20, 100.	0.7	11
21	Successful treatment of a child with idiopathic multicentric Castleman disease associated with hemophagocytic lymphohistiocytosis using tocilizumab. Pediatric Blood and Cancer, 2019, 66, e27759.	0.8	2